PFBT
MLYS icon

Parkside Financial Bank & Trust’s Mineralys Therapeutics MLYS Stock Holding History

Parkside Financial Bank & Trust’s Portfolio MLYS Stock Details MLYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.07K Buy
151
+116
+331% +$3.18K ﹤0.01% 1961
2026
Q1 		$948 Hold
35
– – ﹤0.01% 2378
2025
Q4 		$1.27K Hold
35
– – ﹤0.01% 2254
2025
Q3 		$1.33K Hold
35
– – ﹤0.01% 2167
2025
Q2 		$474 Buy
+35
New +$507 ﹤0.01% 2581

Other funds holding MLYS

CP
Catalys Pacific Tokyo, Japan $229M AUM 100.3% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Parkside Financial Bank & Trust's MLYS Position: Q2 2026 in Review

Parkside Financial Bank & Trust increased its Mineralys Therapeutics (MLYS) stake by 331% in Q2 2026, buying an estimated $3.18K and bringing the position to 151 shares worth $4.07K. The position accounts for ﹤0.01% of the portfolio, ranked #1961.

Parkside Financial Bank & Trust first reported a position in MLYS in Q2 2025 and has held it in 5 quarters since. 225 funds tracked by Wall St. Rank hold MLYS as of Q2 2026.

  • Parkside Financial Bank & Trust held 151 shares of Mineralys Therapeutics worth $4.07K as of Q2 2026.
  • Parkside Financial Bank & Trust bought 116 Mineralys Therapeutics shares in Q2 2026, an estimated $3.18K.
  • Mineralys Therapeutics made up ﹤0.01% of Parkside Financial Bank & Trust's portfolio in Q2 2026, its #1961 holding.
  • Parkside Financial Bank & Trust first reported a position in Mineralys Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • 225 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q2 2026.

Based on Parkside Financial Bank & Trust's 13F filing for Q2 2026, filed 4 Sep 2026.